Navigation Links
New Data on Market-Leading Velcade (Bortezomib) for Injection,Further Strengthen Role in Previously Treated Multiple Myeloma

- Positive data on subcutaneous administration show potential for new option to improve convenience for patients -

CHICAGO, June 04, 2007 /PRNewswire-FirstCall/ -- Millennium Pharmaceuticals, Inc. today announced the presentation of positive data for VELCADE, the market-leading therapy for patients with multiple myeloma (MM) who have received at least one prior therapy. These data include results from a Phase II trial for subcutaneous (SC) administration of VELCADE, a new option under evaluation. Results were also presented from the international Phase III trial of VELCADE + DOXIL, which served as the basis for the recent U.S. approval of the combination and showed significant improvement in time to disease progression compared to VELCADE alone, the current standard of care. The VELCADE + DOXIL abstract was selected by the Best of the American Society of Clinical Oncology (ASCO) Program Committee as one of the premier abstracts at the 43rd Annual Meeting in Chicago.

"We and our partner Johnson & Johnson Pharmaceutical Research and Development L.L.C. continue to develop new clinical data that reinforce the role of VELCADE as the U.S. market-leading therapy in previously treated multiple myeloma," said Nancy Simonian, M.D., Chief Medical Officer, Millennium. "These data demonstrate that VELCADE in combination with another active agent can further strengthen the unparalleled impact of VELCADE. We are aggressively pursuing development of a subcutaneous delivery form to broaden alternatives for patients who prefer to receive VELCADE treatment at home."

Prospective Comparison of Subcutaneous to Intravenous Administration of Bortezomib in Patients with Multiple Myeloma: Pharmacokinetics, Efficacy and Toxicity (Abstract #8046)

This randomized trial evaluated the pharmacokinetics/pharmacodynamics (PK/PD), toxicity and response rate of VELCADE in patients treated with either an SC or intravenous
'"/>




Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Velcade (bortezomib) for Injection Based Induction Therapy Delivered High Post-Transplant Complete Remission Rate, a Critical Marker for Increased Overall Survival
2. Velcade (Bortezomib) for Injection Based Therapies Produced Complete Remission Rates as High as 54 Percent in Patients With Previously Treated Multiple Myeloma
3. Velcade (bortezomib) for Injection Based Therapies Achieved Survival Rates as High as 100 Percent in Newly Diagnosed Multiple Myeloma Patients
4. Velcade (bortezomib) for Injection Survival Data in Front-Line Multiple Myeloma Patients to be Featured at 11th International Myeloma Workshop
5. Study Shows Velcade Plus Doxil Improves Survival in Previously Treated Patients With Multiple Myeloma
6. Millennium Discovers Biomarkers Potentially Predictive of Response to Velcade (Bortezomib) for Injection
7. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
8. Palatin Technologies and King Pharmaceuticals Report Data Showing Improvements in Sexual Relationship and Self-Esteem in Patients with Erectile Dysfunction Treated with Bremelanotide
9. Pegasys Study Authors Conclude that Patients Successfully Treated for Hepatitis C Can be Considered Cured
10. Study Continues to Show Patients With Myelodysplastic Syndromes Treated With Revlimid are Living Longer and Remaining Transfusion Independent
11. Preterm Infants with Respiratory Distress Syndrome: Incidence Rates of Death when Treated with Surfactant Replacement Therapies
Post Your Comments:
(Date:7/11/2014)...  Australian drug delivery company, Phosphagenics Limited (ASX: POH; ... million via a placement of A$16.3 million to institutional ... Asia and Australia ... plan (SPP) to be offered to existing shareholders.  The ... tranches. "This capital raising positions us strongly ...
(Date:7/11/2014)... 11, 2014 Show ... & Health Expo 2014 were a brand ... London , plus a ...          (Logo: http://photos.prnewswire.com/prnh/20130723/629764-a) ... )      (Photo: http://photos.prnewswire.com/prnh/20140711/696892-b ...
(Date:7/10/2014)... Calif. , July 10, 2014  Breg, ... and services, has launched the FreeRunner™ knee brace ... who suffer from patella mal-tracking return to active ... differently than other braces, providing support when patients ... normally when they don,t. Patellofemoral issues ...
Breaking Medicine Technology:Phosphagenics' A$19.3 million Capital Raising 2Phosphagenics' A$19.3 million Capital Raising 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 2UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 3UK's Flagship Health & Safety Event Has Successful Inaugural Year in London 4Breg Introduces Knee Brace to Help Runners with Patellofemoral Pain Syndrome 2
... Ill., July 28, 2011 The National ... health alert to warn Americans about the serious dangers ... report NABP released today on Internet drug outlets found ... to operate out of compliance with United States pharmacy ...
... Boston Scientific Corporation,s (NYSE: BSX ) Board ... repurchase of up to $1.0 billion of its common ... under an existing share repurchase program. "This ... the Company,s long-term business prospects, earnings growth potential and ...
Cached Medicine Technology:NABP Issues Rogue Online Pharmacy Public Health Alert 2NABP Issues Rogue Online Pharmacy Public Health Alert 3NABP Issues Rogue Online Pharmacy Public Health Alert 4Boston Scientific Announces $1.0B Share Repurchase Program 2Boston Scientific Announces $1.0B Share Repurchase Program 3
(Date:7/11/2014)... July 11, 2014 Operators ... $50 billion in fuel costs now that ... current GHG standards are phasing ... it upon themselves to install new features ... 1.    Idle reduction technologies , 2.    Efficient driveline components ...
(Date:7/11/2014)... 11, 2014 Ticket Down is a ... Pavilion . When it comes to the summer concert schedule, ... 37-year-old Georgia native is one of the biggest names in country ... Bryan is currently out on his “That’s My Kind of Night” ... the tour will be making through the rest of the summer ...
(Date:7/11/2014)... 2014 Global enterprises today are shifting ... day-to-day management activities. Managed services offer these global enterprises ... economic slowdown resulted into rising operational costs to companies. ... considered to be the global market driver for expanding ... global managed services market is estimated to grow from ...
(Date:7/11/2014)... R.I. -- Researchers from The Miriam Hospital ... age 65 have significantly higher rates of smoking ... mobility impairments were less likely to attempt quitting ... treatments may not be sufficient for this population. ... in advance of print in the American ...
(Date:7/11/2014)... to repair damage to the anterior cruciate ligament (ACL) -- ... could increase a young athlete,s risk for further injuries, researchers ... aged 8 to 16, who had ACL reconstruction surgery. Of ... their injury, 37 had surgery six to 12 weeks after, ... their injury. The youngsters who had surgery later had ...
Breaking Medicine News(10 mins):Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 2Health News:LeaseQ Agrees the Latest Round of Greenhouse Gas Rules Could Increase the Cost of Truck Acquisition and Maintenance 3Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 2Health News:Luke Bryan Ticket Prices Slashed at Concord Pavilion 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 2Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 3Health News:North America Managed Services Market Worth $68.65 Billion by 2018 - New Report by MicroMarket Monitor 4Health News:Miriam Hospital study examines smoking prevalence 2Health News:Delaying Kid's Knee Surgery Could Be a Bad Play, Study Finds 2
... ... May 15 Meet Cindy Zamirowski, a 56-year-old,breast cancer survivor who less ... stepped off the curb to raise funds for,cancer research in the 5K ... and grandma of three rallied her team of,16 angels at her side ...
... 15 Cleveland Clinic announced today that,the Cleveland ... Reserve,University is providing all its students with full ... Approaching its fifth year in existence, the Cleveland ... training of physician scientists,who are capable of furthering ...
... the Department of Urology have showed that lowering intake of ... prevent prostate cancer in mice, the first finding of its ... researchers said. , The study, which appears in the April ... fat from corn oil, which is made up primarily of ...
... Maxi-K gene therapy may be a safe and effective ... not treatable with oral therapy. Two studies presented today ... Urological Association (AUA) may give hope to these individuals. ... press conference on May 20, 2008 at 10 a.m. ...
... FL, May 20, 2008 Rising global temperatures could ... research presented today at the 103rd Annual Scientific Meeting ... linked to stone disease, particularly in warmer climates, and ... the prevalence of stone disease may increase, along with ...
... 20, 2008 Patients with metabolic syndrome disorders, including ... to develop uric-acid stones than other type of ... 103rd Annual Scientific Meeting of the American Urological ... with uric acid stones could benefit from additional ...
Cached Medicine News:Health News:After Effects: Giving Back Is Good for You 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 2Health News:Cleveland Clinic Lerner College of Medicine to Offer Full Tuition Scholarships for All Students 3Health News:Reducing intake of dietary fat prevents prostate cancer in mice 2Health News:AUA 2008: Maxi-K gene transfer may prove to be safe and effective erectile dysfunction treatment 2Health News:AUA 2008: Uric acid stones may indicate arteriosclerotic diseases 2
Inquire...
Electric Reciprocating Saw, with hand throttle. Can also be purchased without hand throttle (#1915) for use with foot pedal. (#6401-000)...
... without hand throttle, 30,000 RPM, ... medium bur guard included, long ... guards are also available. Must ... (#6401-000), can also be purchased ...
... USA 2001 Universal Battery Charger is manufactured to ... Versipower Plus and 3M MaxiDriver II Battery Packs. ... six Battery Packs simultaneously in less than 40 ... on 120 volt AC grounded electrical power. If ...
Medicine Products: